On October 28, 2025 Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, reported results for the third quarter ended September 30, 2025 and updated full-year guidance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Labcorp’s third-quarter performance reflects continued momentum in our Diagnostics and Central Laboratory businesses, resulting in strong revenue growth and margin improvement," said Adam Schechter, Chairman and CEO of Labcorp. "We advanced our strategy by forming new partnerships with health systems and regional laboratories, introducing innovative tests in key specialty areas and leveraging science and technology to improve customer experience and operational efficiency. Our performance led to double-digit adjusted EPS growth and strong cash flow in the quarter. We expect to finish the year strong as we remain focused on delivering value to our customers and shareholders."

Labcorp advanced its position as a partner of choice for health systems and regional/local laboratories. In the quarter, Labcorp:

Signed an agreement to acquire select assets of Empire City Laboratories, which serves the New York Tri-State area.
Signed an agreement to acquire select assets of Laboratory Alliance of Central New York, a pathology reference laboratory, and signed an agreement with Crouse Health to manage its inpatient labs.
Continued to progress the acquisition of select assets of the outreach business from Community Health Systems across 13 states.
Completed the acquisition of select oncology and clinical testing assets from BioReference Health, further solidifying Labcorp’s position as an industry leader in oncology.
The company also continued to incorporate the power of science, technology and innovation across the organization. In the quarter, Labcorp:

Expanded its leading oncology and genetic testing portfolio.
Labcorp expanded the use of OmniSeq INSIGHT, which now evaluates ovarian tumors for homologous recombination deficiency.
PGDx elio tissue complete became the first and remains the only tissue-based tumor profiling test with CE-marking under the European Union’s In Vitro Diagnostic Regulation.
Geneoscopy received FDA approval for a simplified at-home collection method for ColoSense, its RNA-based colorectal cancer screening test that Labcorp will make available to patients and providers.
The company expanded access to its Invitae genetic tests through Epic Aura, enabling streamlined ordering and results delivery for Epic customers.
Expanded its leadership in neurology with two new Alzheimer’s tests to be used in the specialty and primary care settings.
Demonstrated strong momentum in its consumer business with the introduction of several new tests through Labcorp OnDemand.
Accelerated growth, enhanced the customer experience and improved operational efficiency through the launch of Labcorp Test Finder and investments in digital and AI capabilities to enhance areas such as pathology, cytology and microbiology.
On October 8, 2025, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on December 11, 2025, to stockholders of record at the close of business on November 26, 2025. In the quarter, Labcorp repurchased $25 million of common stock.

(Press release, LabCorp, OCT 28, 2025, View Source [SID1234657069])